January 20, 2022 – Unilever (London, UK), which was reported to push further into health, beauty and hygiene products earlier this week, has effectively backed away from the $68 billion offer for GlaxoSmithKline’s (GSK) consumer-healthcare business as it won’t increase its offer. The announcement came after criticism from analysts and investors about the price and the strategic fit. GSK said the company was confident in the future of the consumer-healthcare business.